OneChain Immunotherapeutics is advancing the future of CAR-T with a differentiated in vivo platform designed for scalable, accessible cancer immunotherapy. Our ongoing autologous clinical program in T-cell malignancies underpins a pipeline focused on transforming how cell therapies are delivered.
Founded on pioneering research led by Dr Pablo Menendez at the Josep Carreras Leukemia Research Institute and ICREA, OneChain continues to advance innovative approaches for cancer patients.